- EB 136 Friday, January 30th: Discussion of Consultative Expert Working Group on Research Development-Financing and Coordination
- EB 136 Friday, January 30th: Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property
- EB 136 Tuesday January 28: WHO Engagement with Non-state Actors; US issues apology to the African Group
- Argentina, Brazil, India and South Africa- Draft decision to extend mandate of Global Strategy and Plan of Action till 2022
- EB 136 WHO Special Session: Unanimous Ebola Resolution [finally reached on Sunday]
- WTO TRIPS Council (October 2014): Bangladesh statement (on behalf of LDCs)- Extension of the 2016 transition period
- EB136: WHO outlines contours of a Pooled Fund for Global Health Research and Development
- EB136: WHO Evaluation of the global strategy and plan of action on public health, innovation and intellectual property
- SCCR29: Summary By the Chair
- SCCR 29 Chair Proposed Summary for Broadcasting treaty
Comité Permanente de Derechos de Autor y Conexos – SCCR 22 – OMPI - Ginebra
Intervención de la Delegación de Uruguay. Ginebra, 15 de junio de 2011.
Gracias Señor Presidente,
Señor Presidente, reciba de nuestra delegación nuestras mas sinceras felicitaciones por su designación como Presidente del Comité Permanente de Derechos de Autor y Conexos SCCR y cuente con nuestro apoyo para hacer una exitosa gestión al frente de este importante comité.
White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs)Submitted by James Love on 11. June 2011 - 9:36
KEI Policy Brief 2011:1
June 11, 2011, Revised August 15, 2011
Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.
These are the data:
2010 Global R&D by all private companies: - $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
2010 Global sales - $856 billion
KEI Intervention at UN HLM on HIV: De-Linking R&D costs from drug prices and the sustainability of treatmentSubmitted by James Love on 9. June 2011 - 4:43
These are the notes from my intervention today at the UN's High Level Meeting on HIV/AIDS in New York. The persons making statements from the floor were asked to keep their comments to two minutes, so the actual intervention was somewhat shorter. Jamie
the comprehensive review of the progress achieved in realizing
the Declaration of Commitment on HIV/AIDS and
NYC, 7 PM Wed, June 8, 2011.
On Wednesday, 25 May 2011, the 129th session of the World Health Organization's Executive Board approved Decision, EB129(8) on "WHO reform for a healthy future". Reproduced below is the text of the Decision which is yet to be published on the WHO website in all 6 UN languages.
EB129(8) WHO reform for a healthy future
The Executive Board,
Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countriesSubmitted by James Love on 27. May 2011 - 16:15
KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.
Senator Sanders introduces two medical innovation prize bills in U.S. Senate to de-link R&D costs from drug pricesSubmitted by James Love on 27. May 2011 - 4:53
There is a growing interest in the use of innovation inducement prizes to stimulate investments in medical research and development.
- The Obama Administration and the European Commission are exploring the role of innovation inducement prizes.
- On May 31, 2011, the European Parliament is holding one of several meetings on innovation inducement prizes for medical technologies.
At 18:30 Geneva time on 25 May 2011, during the 129th session of the WHO Executive Board, the EB is considering the following draft decision on WHO reform.
Chair's text, based on draft proposed by Ecuador
The 29th [sic] Executive Board,
(OP.1) DECIDES to establish an incremental, transparent, Member-State driven and inclusive consultative process comprising of the following elements:
Letter to the 129th WHO Executive Board on conflicts of interest, WHO reform and the future of financingSubmitted by thiru on 24. May 2011 - 4:00
24 May 2011
NGO letter on Conflicts of Interest, Future Financing, Reform and governance of the WHO.
Dear Members of the Executive Board,
World Intellectual Property Organization
DATE: MAY 20, 2011
Standing Committee on the Law of Patents
Geneva, May 16 to 20, 2011
SUMMARY BY THE CHAIR
Agenda Item 1: Opening of the session
1. The sixteenth of the Standing Committee on the Law of Patents (SCP) was opened by Mr. James Pooley, Deputy Director General, who welcomed the participants. Mr. Philippe Baechtold (WIPO) acted as Secretary.
BRICS Health Ministers’ preparatory meeting – May 17th 2011
Consistent with the mandate of the Sanya Declaration of the BRICS Leaders Meeting (14 April 2011), the Ministers of Health of the five BRICS’ countries met on the sidelines of the 64thWorld Health Assembly, on 17 May 2011, to discuss issues of common interest as well as prepare the BRICS Health Ministerial Meeting to be held in Beijing, China, on 11 July 2011. Representatives of WHO and UNAIDS also attended the meeting.
16th session of the WIPO Standing Committee of the Law of Patents (SCP)
Thursady, 19 May 2011
KEI Statement on Patents and Health
KEI is impressed by and fully supportive of the joint proposal of the African Group and the Development Agenda Group on a work program on Patents and Health, which has been published as SCP/16/7. We agree with the comments of the Chair that the proposal is both comprehensive and well thought out.
Civil Society on transparency, public health in TPPA; 28 Senators call for highest standards of protection IP in agreementSubmitted by Krista Cox on 18. May 2011 - 15:32
On Wednesday, May 18, 2011, eight civil society organizations submitted joint comments and recommendations on the Trans-Pacific Partnership Agreement (TPPA).